Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized, Multi Center Study Of Sunitinib Malate (SU 011248) Or Capecitabine In Subjects With Advanced Breast Cancer Who Failed Both A Taxane And An Anthracycline Chemotherapy Regimen Or Failed With A Taxane And For Whom Further Anthracycline Therapy Is Not Indicated

NCT00373113 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00373113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00373113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized, Multi Center Study Of Sunitinib Malate (SU 011248) Or Capecitabine In Subjects With Advanced Breast Cancer Who Failed Both A Taxane And An Anthracycline Chemotherapy Regimen Or Failed With A Taxane And For Whom Further Anthracycline Therapy Is Not Indicated
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2006
Completion date
June 30, 2011
Enrollment
482 (actual)
Sites
123

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms